# US 2019/0167788 A1 · Composition and Method for Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167788 A1
- Document ID: US20190167788A1
- Status: Published application
- Kind: A1
- Application number: 16/271,388
- Filed: 2019-02-08
- Published: 2019-06-06
- Earliest claimed: 2011-01-13
- Assignees: OncBioMune, L.L.C.
- Applicants: OncBioMune, Inc.
- Inventors: Jonathan F. Head; Robert L. Elliott
- Web page: https://patentgrep.com/patent/US20190167788A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/20: Interleukins [IL]
- A61K 39/001139: {Colony stimulating factors [CSF]}
- A61K 39/00114: {Interleukins [IL]}
- A61K 39/001182: {Carcinoembryonic antigen [CEA]}
- A61K 39/001194: {Prostate specific antigen [PSA]}
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55533: {IL-2}
- A61K 2039/80: {Vaccine for a specifically defined cancer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same.

## Claims

### Claim 1

A composition comprising (i) a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer; (ii) at least one interleukin (IL); and (iii) at least one colony stimulating factor (CSF), wherein the protein is provided in an amount sufficient to induce an immune response in an individual administered the composition.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the surface or excreted protein comprises prostate specific antigen (PSA).

### Claim 3 (depends on 1)

The composition of claim 1, comprising about 50 μg PSA, about 2 μg CEA, about 1000 IU CA 125, about 20,000 units IL-2, and about 16.7 μg GM-CSF, per 100 μL of composition.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the surface or excreted protein comprises CA 125 or CA 15-3, or a combination thereof.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the surface or excreted protein is selected from prostatic acid phosphatase (PAP), prostate specific membrane antigen (PSMA), carcino-embryonic antigen (CEA), CA 27.29, α-feto protein (AFP), estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (Her-2/neu), lipid-associated sialic acid in plasma (LASA-P), CA 72-4, bladder tumor antigen (BTA), tissue polypeptide antigen (TPA), neuron specific enolase (NSE), chromogranin A, CA 19-9, CA 50, calcitonin, thyroglobulin, S-100, tumor associated antigen 90 (TA-90), β-2 microglobulin, nuclear matrix protein 22 (NMP 22), β-human chorionic gonadotropin (β-hCG), and chromogranin A (CgA).

### Claim 6 (depends on 1)

The composition of claim 1, wherein the IL is selected from IL-1, IL-2, IL-3, IL-4, IL-5, IL-6 IL-7, IL-9, IL-12, IL-13, IL-14 and IL-15.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the CSF is selected from GM-CSF, G-CSF and M-CSF.

### Claim 8 (depends on 1)

The composition of claim 1, comprising IL-2 and GM-CSF.

### Claim 9 (depends on 1)

The composition of claim 1, which further comprises at least one additional purified protein associated with the type of cancer.

### Claim 10 (depends on 1)

The composition of claim 1, which comprises about 1 μg to about 1000 μg of the protein per 100 μL of the composition.

### Claim 11 (depends on 10)

The composition of claim 10, which comprises about 1 μg to about 250 μg of the protein per 100 μL of the composition.

### Claim 12 (depends on 9)

The composition of claim 9, which comprises about 1 μg to about 1000 μg of each protein per 100 μL of the composition.

### Claim 13 (depends on 12)

The composition of claim 12, which comprises about 1 μg to about 250 μg of the protein per 100 μL of the composition.

### Claim 14 (depends on 1)

The composition of claim 1, which comprises about 0.3 μg to about 3 μg of interleukin and about 10 to about 100 μg of CSF per 100 μL of composition.

### Claim 15 (depends on 14)

The composition of claim 14, which comprises about 0.3 μg to about 3 μg of interleukin and about 15 to about 20 μg of CSF per 100 μL of composition.

### Claim 16 (depends on 9)

The composition of claim 9, which comprises about 0.6 μg to about 1.8 μg of interleukin and about 10 to about 100 μg of CSF per 100 μL of composition.

### Claim 17 (depends on 16)

The composition of claim 16, which comprises about 0.6 μg to about 1.8 μg of interleukin and about 15 μg to about 20 μg of CSF per 100 μL of composition.

### Claim 18 (depends on 1)

A method for treating an individual comprising administering to an individual having a type of cancer, a therapeutically effective amount of a composition of claim 1.

### Claim 19 (depends on 1)

A method for inducing an immunotherapeutic response in an individual comprising administering to an individual diagnosed with a type of cancer a therapeutically effective amount of composition of claim 1, wherein composition comprises the purified surface or excreted protein in an amount sufficient to induce an immunotherapeutic response in the individual.